- Home
- FLYX vs COEP Comparison
FLYX vs COEP Comparison
Compare FLYX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- COEP
- Stock Information
- Founded
- FLYX 2015
- COEP 2017
- Country
- FLYX United States
- COEP United States
- Employees
- FLYX N/A
- COEP N/A
- Industry
- FLYX Blank Checks
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLYX Finance
- COEP Health Care
- Exchange
- FLYX Nasdaq
- COEP Nasdaq
- Market Cap
- FLYX 102.4M
- COEP 86.0M
- IPO Year
- FLYX N/A
- COEP N/A
- Fundamental
- Price
- FLYX $4.25
- COEP $16.76
- Analyst Decision
- FLYX
- COEP
- Analyst Count
- FLYX 0
- COEP 0
- Target Price
- FLYX N/A
- COEP N/A
- AVG Volume (30 Days)
- FLYX 55.1K
- COEP 65.4K
- Earning Date
- FLYX 11-13-2025
- COEP 11-12-2025
- Dividend Yield
- FLYX N/A
- COEP N/A
- EPS Growth
- FLYX N/A
- COEP N/A
- EPS
- FLYX N/A
- COEP N/A
- Revenue
- FLYX $347,746,000.00
- COEP $263,555.00
- Revenue This Year
- FLYX $28.47
- COEP N/A
- Revenue Next Year
- FLYX $22.44
- COEP N/A
- P/E Ratio
- FLYX N/A
- COEP N/A
- Revenue Growth
- FLYX 17.09
- COEP N/A
- 52 Week Low
- FLYX $1.79
- COEP $2.31
- 52 Week High
- FLYX $6.90
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- FLYX 46.95
- COEP 60.80
- Support Level
- FLYX $3.87
- COEP $16.00
- Resistance Level
- FLYX $5.55
- COEP $18.15
- Average True Range (ATR)
- FLYX 0.58
- COEP 1.60
- MACD
- FLYX -0.16
- COEP 0.07
- Stochastic Oscillator
- FLYX 14.01
- COEP 66.80
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.